Figure 2From: Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]Percentage of men withdrawing from randomised treatment during the first 3 years.Back to article page